ZEB1 expression is frequently detected in undifferentiated and de‐differentiated carcinomas, but is not specific among endometrial carcinomas. Issue 1 (18th May 2022)

• Record Type: Journal Article
• Authors: Kihara, Atsushi; Amano, Yusuke; Fukushima, Noriyoshi; Fujiwara, Hiroyuki; Niki, Toshiro
• Is Part Of: Histopathology. Volume 81:Issue 1(2022)
• Page Start: 108
• Page End: 118
• Publication Date: 2022-05-18
• Subjects: de‐differentiated carcinoma -- grade 3 endometrioid carcinoma -- undifferentiated carcinoma -- uterine corpus -- ZEB1; Histology, Pathological -- Periodicals; 611.018
• DOI: 10.1111/his.14671
• Languages: English
• ISSNs: 0309-0167

Abstract

Abstract : Aims: The pathological diagnosis of undifferentiated and de‐differentiated endometrial carcinomas (UC/DCs) is prognostically important. However, undifferentiated components may be confused with other subtypes, particularly grade 3 endometrioid carcinomas (G3ECs). Zinc finger E‐box binding homeobox 1 (ZEB1) has recently been identified as a promising marker because it is frequently expressed in the undifferentiated components of UC/DCs, but not in other carcinomas. Therefore, we herein evaluated the diagnostic utility of ZEB1 with an emphasis on distinguishing between UC/DCs and G3ECs using an expanded cohort of endometrial carcinomas and carcinosarcomas. Methods and results: Immunostaining for ZEB1 was performed on whole‐tissue sections of 19 UC/DCs, 194 non‐UC/DC endometrial carcinomas and 29 carcinosarcomas. Staining was defined as negative (< 5%), focal (5–50%) and diffuse expression (> 50%). ZEB1 was expressed in 84% of the undifferentiated components of UC/DCs (diffuse in 14, focal in two). Focal expression was observed in eight non‐UC/DC endometrial carcinomas and diffuse expression in seven, with the latter comprising G3ECs (four of 76), serous carcinoma (one of 37), clear cell carcinoma (one of 21) and neuroendocrine carcinoma (one of three). Epithelial differentiation was morphologically and immunohistochemically less evident in G3ECs and neuroendocrine carcinoma with diffuse ZEB1 expression. All carcinosarcomas showed diffuse ZEB1 expression in their sarcomatous components. Conclusion: Immunostaining for ZEB1 was sufficiently sensitive to detect undifferentiated components. Diffuse ZEB1 expression showed high specificity for distinguishing between undifferentiated components and G3ECs; however, ZEB1 expression was not entirely specific to UC/DCs. The integration of ZEB1 into the diagnosis of UC/DCs requires careful examination to exclude other tumours, such as less differentiated G3ECs, neuroendocrine carcinomas and carcinosarcomas. Abstract :